O' (happy) Day? :) Only yesterday: "While th
Post# of 148294
Only yesterday:
"While the “vast majority of deals will still be earlier stage by definition,” investors should “rest assured” that Gilead is working to supplement its late-stage portfolio through M&A, too. As it does, it’ll be looking for targets that fit into its core areas of viral diseases, inflammatory diseases, fibrotic diseases and oncology, with a particular focus on immuno-modulatory drugs. "
https://www.fiercepharma.com/pharma/want-clue...pagos-deal